Viking Therapeutics, Inc. (VKTX) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

1.56 M

Shareholding (Mar 2025)

FII

12.27%

Held by 183 FIIs

DII

44.05%

Held by 52 DIIs

Promoter

1.00%

How big is Viking Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Viking Therapeutics, Inc. has a market capitalization of $2.97 billion, with net sales of $0 and a net profit of -$128.24 million over the last four quarters. The company reported shareholder's funds of $880.28 million and total assets of $908.32 million as of Dec 24.

What does Viking Therapeutics, Inc. do?

22-Jun-2025

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic and endocrine disorders. It has a market cap of approximately $2.97 billion and reported a net profit loss of $46 million as of March 2025.

Who are in the management team of Viking Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Viking Therapeutics, Inc. includes Dr. Lawson Macartney (Independent Chairman), Dr. Brian Lian (President and CEO), and Directors Matthew Foehr, S. Kathy Rouan, Charles Rowland, and J. Matthew Singleton. They oversee the company's strategic direction and operations.

Is Viking Therapeutics, Inc. technically bullish or bearish?

05-Nov-2025

As of October 31, 2025, the trend has shifted to mildly bullish due to positive indicators on shorter timeframes, despite mixed signals from longer-term metrics and significant underperformance against the S&P 500 over the past year.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 2,865 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.01

Return on Equity

-21.57%

Price to Book

3.60

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-66 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

43.76%

6 Months

44.95%

1 Year

-23.26%

2 Years

196.46%

3 Years

805.4%

4 Years

685.54%

5 Years

512.22%

Viking Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Is Viking Therapeutics, Inc. technically bullish or bearish?

As of 31 October 2025, the technical trend has changed from mildly bearish to mildly bullish. The current stance is mildly bullish, driven by a bullish MACD on the weekly timeframe and bullish moving averages on the daily timeframe. However, the monthly MACD and Bollinger Bands indicate bearish conditions, suggesting mixed signals across different periods. The stock has underperformed the S&P 500 over the year and year-to-date, with returns of -52.48% and -13.94% respectively, but has significantly outperformed over the 3-year and 5-year periods with returns of 687.05% and 498.10%....

Is Viking Therapeutics, Inc. technically bullish or bearish?

As of 31 October 2025, the technical trend for Viking Therapeutics, Inc. has changed from mildly bearish to mildly bullish. The weekly MACD is bullish, while the monthly MACD remains bearish. The daily moving averages are bullish, indicating short-term strength. However, the weekly KST and OBV are mildly bearish, suggesting some caution. The Bollinger Bands show a bullish signal on the weekly timeframe but are mildly bearish on the monthly. According to Dow Theory, the weekly stance is mildly bullish, while the monthly is mildly bearish. In terms of performance, the stock has underperformed the S&P 500 year-to-date and over the past year, with returns of -10.54% and -50.60%, respectively, compared to the S&P 500's 16.30% and 19.89%. However, it has significantly outperformed over the 3-year and 5-year periods, with returns of 718.18% and 521.76%, respectively, against the S&P 500's 76.66% and 109.18%. Ove...

Is Viking Therapeutics, Inc. technically bullish or bearish?

As of 31 October 2025, the technical trend for Viking Therapeutics, Inc. has changed from mildly bearish to mildly bullish. The weekly MACD is bullish, while the monthly MACD remains bearish, indicating mixed signals across time frames. The daily moving averages are bullish, supporting the positive shift in trend. However, the weekly and monthly KST and OBV are mildly bearish, suggesting some caution. The Dow Theory shows a mildly bullish stance on the weekly chart but is bearish on the monthly. In terms of performance, the stock has significantly outperformed the S&P 500 over the past week and month, with returns of 10.63% and 39.13%, respectively, compared to 0.71% and 1.92% for the index. However, over the longer term, the stock has underperformed, with a year-to-date return of -5.37% versus the S&P 500's 16.30%, and a one-year return of -47.50% compared to 19.89% for the index. Overall, the current sta...

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-229.34%

EBIT to Interest (avg)

-92.99

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.01

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

86.58%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

3.69

EV to EBIT

-13.20

EV to EBITDA

-13.23

EV to Capital Employed

-511.98

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-15.14%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Bearish

RSI

No Signal

Bollinger Bands

Bullish

Bearish

Moving Averages

Bullish (Daily)

KST

Bullish

Mildly Bearish

Dow Theory

No Trend

Mildly Bullish

OBV

No Trend

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 99 Schemes (42.68%)

Foreign Institutions

Held by 183 Foreign Institutions (12.27%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -194.17% vs -16.15% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-74.50",
          "val2": "-34.00",
          "chgp": "-119.12%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-65.60",
          "val2": "-22.30",
          "chgp": "-194.17%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -28.06% vs -24.67% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-150.60",
          "val2": "-100.50",
          "chgp": "-49.85%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-110.00",
          "val2": "-85.90",
          "chgp": "-28.06%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-74.50

-34.00

-119.12%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-65.60

-22.30

-194.17%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -194.17% vs -16.15% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-150.60

-100.50

-49.85%

Interest

0.10

Exceptional Items

0.00

Consolidate Net Profit

-110.00

-85.90

-28.06%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -28.06% vs -24.67% in Dec 2023

All Annual Results

Company CV

About Viking Therapeutics, Inc.

Viking Therapeutics, Inc.

Pharmaceuticals & Biotechnology

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company's clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery. VK5211 is a non-steroidal selective androgen receptor modulator (SARM). Its second program is focused on the development of orally available small molecule thyroid hormone receptor beta agonists. Its two molecules are VK2809 and VK0214. VK2809 is an orally available, tissue and receptor-subtype selective agonist of the thyroid beta receptor that is entering Phase II development for the treatment of patients with hypercholesterolemia and fatty liver disease. It is developing VK0214 for the treatment of X-linked adrenoleukodystrophy (X-ALD). It has a pipeline with approximately three additional programs targeting metabolic diseases and anemia.

Company Coordinates

Company Details

12340 El Camino Real Ste 250 , SAN DIEGO CA : 92130-3093

Tel: 1 858 70446601 858 7044672

http://www.vikingtherapeutics.com

Registrar Details

Viking Therapeutics, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Viking Therapeutics, Inc.?

Watch in Real-Time

What does Viking Therapeutics, Inc. do?

Who are in the management team of Viking Therapeutics, Inc.?

Is Viking Therapeutics, Inc. technically bullish or bearish?

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Is Viking Therapeutics, Inc. technically bullish or bearish?

Is Viking Therapeutics, Inc. technically bullish or bearish?

Is Viking Therapeutics, Inc. technically bullish or bearish?

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Viking Therapeutics, Inc.

Company Coordinates